Friday, March 17, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

NAMRU-3, Stanford Work to Combat Acute Febrile Illness

by Global Biodefense Staff
August 24, 2015
NAMRU-3 U.S. Naval Medical Research Unit

The Naval Medical Research Center (NMRC) has announced intentions to award a contract to Stanford University to support biosurveillance and biosecurity activities in Liberia.

The effort specifically focuses on known and novel etiologies of Acute Febrile Illness in rural Liberia. Stanford will perform a range of biosurveillance-oriented activities under the effort, including:

  • Training, management and supervision of in-country joint Liberian National and Naval Medical Research Unit Three (NAMRU-3) teams
  • Collection of primary data for epidemiological analysis of the incidence of Acute Febrile Illness
  • Analysis of data and development of population-based estimates on disease occurrence
  • Generation of status reports and final analysis products for publication
  • Liaison activities with local hospital staff at the Kolahun Regional Hospital and the Liberian Institute for Biomedical Research
  • Integration of Kolahun Regional Hospital into the Acute Febrile Illness project
  • Assist with preparation and submission of an Institutional Review Board protocol
  • Define a catchment Area of the population served by the Foya Hospital and disseminated community clinics in Lofa County, Liberia

NAMRU-3 is a U.S. Department of Defense biomedical research laboratory based in Cairo, Egypt. The organization has been working to increase biosurveillance systems and biosecurity across Africa and the Middle East since 1942. NAMRU-3 works closely with the Egyptian Ministry of Health, the U.S. National Institutes of Health, the World Health Organization (WHO), the U.S. Agency for International Development, and the U.S. Centers for Disease Control and Prevention on evaluation of vaccines, therapeutic agents, diagnostic assays, and vector control measures for the region.

The NAMRU-3 mission includes public health activities and capacity building in cooperation with host countries in the region, and the organization was named as a WHO Collaborating Center for Emerging and Re-Emerging Infectious Diseases in 2001. NAMRU-3 also serves as a WHO reference laboratory for influenza and meningitis in the Eastern Mediterranean Region.

Tags: Awards

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Pursues Advanced Threat-Detection for Crop Defense
Biosecurity

DARPA Pursues Advanced Threat-Detection for Crop Defense

January 3, 2023
New Virus Discovered in Swiss Ticks
Biosurveillance

New Virus Discovered in Swiss Ticks

December 7, 2022
Paxlovid Has Been Free So Far. Next Year, Sticker Shock Awaits.
Health Security

Paxlovid Has Been Free So Far. Next Year, Sticker Shock Awaits.

December 7, 2022
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC